diabetes Archive
-
September 6, 2023
Update: Dame Frances Ashcroft to deliver Sept. 14 Vanderbilt Prize Lecture
Renowned diabetes expert Professor Dame Frances Ashcroft, recipient of the 2023 Vanderbilt Prize in Biomedical Science, will deliver her Vanderbilt Prize Discovery Lecture at 4 p.m. Thursday, Sept. 14, in 208 Light Hall. -
August 2, 2023
VUMC receives $28 million to lead national study of COVID-diabetes link
Researchers at Vanderbilt University Medical Center have received a four-year, $28 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases to study the relationship between COVID-19 and diabetes. -
August 2, 2023
The urgency of research
Griffin Rodgers, MD, director of the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, described the urgency of the nation’s diabetes epidemic July 26 during a symposium of the NIDDK Medical Student Research Program in Diabetes and Obesity hosted by Vanderbilt University. -
June 13, 2023
Maternal diet influences postnatal diabetes risk
Studies in a primate animal model suggest that islet hyperfunction — which in humans is associated with increased fat mass and Type 2 diabetes — is programmed in offspring by a maternal Western-style diet during pregnancy. -
May 8, 2023
Diabetes drugs associated with fewer adverse cardiac events in older veterans: study
Vanderbilt research finds that GLP1 receptor agonists — a class of diabetes medications — are associated with fewer major adverse cardiovascular events than another type of diabetes drug (DPP4 inhibitors) in older veterans with no prior heart disease. -
April 24, 2023
Kenneth Reynolds weighed 780 lbs., and his body was shutting down. Vanderbilt Weight Loss Center gave him back his life.
Coming up: going fishing with his grandchildren -
March 23, 2023
Study sheds light on drug’s impact on diabetes progression
A Vanderbilt study of a treatment to delay the development of Type 1 diabetes in individuals at high risk did not meet the study goals of delaying progression from normal glucose tolerance to abnormal glucose tolerance or clinical diagnosis, although the study drug, abatacept, impacted immune response and preserved insulin production during the one-year treatment period.